Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous or intravenous recombinant human neuregulin-1 in chronic systolic heart failure
ChiCTR-TRC-10000992Phase 3Suspended
- Sponsor
- Fuwai Hospital
- Start
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of neucardin in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Fuwai Hospital. Primary endpoints: NYHA functional class and Cardiac function by MRI. Started Jul 2010; status: suspended.
02
Drugs
neucardin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR-TRC-10000992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10000992.